查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1785351

連網藥物輸送設備市場－全球產業規模、佔有率、趨勢、機會及預測，依產品類型、給藥途徑、應用、地區及競爭細分，2020-2030 年預測

Connected Drug Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product Type, By Route of Administration, By Application, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年，全球連網藥物輸送設備市場規模達64.5億美元，預計2030年將達151.5億美元，複合年成長率為15.25%。全球連網藥物輸送設備市場正在經歷重大變革，其驅動力包括先進數位技術的整合、醫療服務模式的轉變，以及對個人化、結果導向醫療的日益重視。這些新一代藥物傳輸系統配備嵌入式感測器、藍牙連接、配套行動應用程式和雲端分析功能，旨在增強患者服藥依從性，提供切實可行的健康洞察，並改善長期治療效果，尤其適用於慢性病管理。

市場概覽
預測期 2026-2030
2024年市場規模 64.5億美元
2030年市場規模 151.5億美元
2025-2030 年複合年成長率 15.25%
成長最快的領域 腸外
最大的市場 北美洲

該市場處於醫療創新、數位轉型和醫藥進步的交匯點，發展勢頭強勁。包括生物製藥公司、醫療科技公司、支付方和醫療服務提供者在內的整個生態系統的利益相關者正在積極投資互聯治療平台，這些平台支援遠端監控、自動化依從性追蹤並實現即時患者互動。隨著監管框架的日趨成熟和數位醫療報銷的更加結構化，該市場將迅速擴張，尤其是在慢性病負擔日益加重、數位化基礎設施日益完善的地區。互聯藥物輸送領域已不再是小眾市場，而是正在成為未來精準醫療和去中心化醫療服務交付的策略支柱。

關鍵市場促進因素

需要長期服藥的慢性病盛行率上升

主要市場挑戰

設備成本高且報銷支援有限

主要市場趨勢

將人工智慧 (AI) 和高級分析整合到互聯設備中

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：連網藥物輸送設備市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品類型（獨立組件和軟體、整合設備）
    • 依給藥途徑（腸胃外、吸入）
    • 依應用（氣喘、慢性阻塞性肺病、糖尿病管理、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美連網藥物傳輸設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲聯網藥物輸送設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章：亞太聯網藥物傳輸設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美聯網藥物輸送設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲聯網藥物輸送設備市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章：全球連網藥物輸送設備市場：SWOT 分析

第 14 章：競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • Novo Nordisk A/S
  • Phillips Medisize
  • Medtronic Plc.
  • Adherium Limited
  • Tandem Diabetes Care, Inc.
  • Biocorp Life Sciences Pvt. Ltd
  • Resmed Corp
  • Ypsomed AG
  • AptarGroup, Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 7438

Global Connected Drug Delivery Devices market was valued at USD 6.45 Billion in 2024 and is expected to reach USD 15.15 Billion by 2030 with a CAGR of 15.25%. The Global Connected Drug Delivery Devices Market is undergoing a significant evolution, shaped by the integration of advanced digital technologies, shifting healthcare delivery models, and the rising emphasis on personalized, outcomes-driven care. These next-generation drug delivery systems equipped with embedded sensors, Bluetooth connectivity, companion mobile apps, and cloud-based analytics are purpose-built to enhance medication adherence, deliver actionable health insights, and improve long-term treatment outcomes, particularly for chronic disease management.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.45 Billion
Market Size 2030USD 15.15 Billion
CAGR 2025-203015.25%
Fastest Growing SegmentParenteral
Largest MarketNorth America

Positioned at the nexus of healthcare innovation, digital transformation, and pharmaceutical advancement, this market is gaining strong momentum. Stakeholders across the ecosystem including biopharma companies, medtech firms, payers, and providers are actively investing in connected therapeutic platforms that support remote monitoring, automate adherence tracking, and enable real-time patient engagement. As regulatory frameworks mature and digital health reimbursement becomes more structured, the market is set to scale rapidly, especially in regions with growing chronic disease burdens and increasing digital infrastructure. The connected drug delivery landscape is no longer a niche it's emerging as a strategic pillar in the future of precision medicine and decentralized care delivery.

Key Market Drivers

Rising Prevalence of Chronic Diseases Requiring Long-Term Medication

The escalating global burden of chronic diseases is a primary catalyst fueling the growth of the Global Connected Drug Delivery Devices Market. Chronic diseases such as cardiovascular disorders, cancer, diabetes, and chronic respiratory illnesses now represent the primary drivers of mortality and long-term disability worldwide. These conditions account for approximately 75% of all global deaths, underscoring their disproportionate impact on both public health and economic productivity. Chronic diseases account for nearly three-quarters of global deaths and continue to rise due to aging populations, sedentary lifestyles, urbanization, and poor dietary habits.

Over 537 million adults are currently living with diabetes, a number expected to exceed 783 million by 2045. According to the Global Initiative for Asthma (GINA), asthma remains one of the most widespread chronic non-communicable diseases, impacting more than 260 million individuals globally. It is a major contributor to global morbidity and is linked to over 450,000 deaths annually. The high incidence and mortality associated with asthma reflect a persistent gap in disease control, adherence, and access to effective management tools particularly in underserved regions. This highlights a growing market opportunity for connected respiratory drug delivery solutions that can improve treatment precision, monitor patient adherence in real time, and reduce preventable asthma-related complications. These diseases often require daily or weekly medication regimens involving injectables, inhalers, or complex drug delivery protocols. This rapidly growing patient pool directly increases demand for connected devices that ensure accurate dosing, adherence tracking, and ongoing patient support.

Medication non-adherence is a major concern in chronic disease management, leading to worsening health outcomes, increased hospitalizations, and higher healthcare costs. Research consistently indicates that 40% to 60% of patients managing chronic conditions exhibit poor medication adherence, frequently skipping doses, mismanaging dosage schedules, or discontinuing treatment prematurely. Connected drug delivery devices help solve this challenge by: Providing automated reminders and alerts through mobile apps. Tracking real-time usage and sending adherence data to healthcare providers. Enabling patient engagement through visual feedback, usage history, and digital coaching. By improving adherence, these devices not only enhance clinical outcomes but also align with the priorities of healthcare payers and providers who are focused on value-based care delivery. Patients with chronic conditions often require long-term, consistent drug administration that can be managed at home without the need for frequent clinic visits. Connected drug delivery devices support this transition by enabling: Self-injection or inhalation with minimal training, even for biologics and specialty medications. Real-time feedback to ensure correct usage, minimizing the risk of administration errors. Remote data sharing with physicians, allowing for continuous therapy optimization and proactive intervention. This functionality is especially crucial for diseases like rheumatoid arthritis, multiple sclerosis, and hormone disorders, where biologics and specialty injectables are becoming the standard of care.

Key Market Challenges

High Cost of Devices and Limited Reimbursement Support

One of the most significant barriers to market expansion is the high upfront cost associated with connected drug delivery devices, especially compared to traditional drug administration methods. These devices often incorporate advanced features such as Bluetooth connectivity, integrated sensors, and cloud-based data transmission all of which increase production costs.

For healthcare providers and payers, especially in price-sensitive markets, justifying the added cost becomes challenging without a clear and quantifiable return on investment (ROI). Reimbursement frameworks remain fragmented and inconsistent across regions. In many countries, connected devices are not fully covered under public or private insurance plans, limiting patient accessibility particularly in low- and middle-income economies. Additionally, the cost of accompanying digital infrastructure (such as mobile apps, cloud platforms, and device integration with EHRs) can further complicate adoption. Until reimbursement models evolve to recognize the long-term cost savings of improved adherence and reduced hospitalizations, affordability will continue to be a limiting factor.

Key Market Trends

Integration of Artificial Intelligence (AI) and Advanced Analytics into Connected Devices

One of the most significant trends shaping the future of connected drug delivery devices is the integration of AI and real-time analytics. Modern devices are evolving from passive tracking tools into intelligent therapeutic systems capable of learning from user data and dynamically optimizing treatment regimens.

Predictive dosing algorithms can now analyze historical adherence data, biometrics (e.g., blood glucose levels), and behavioral trends to fine-tune dosage recommendations in real time. AI-driven insights allow early identification of non-compliance, adverse events, or therapy deviations, which helps healthcare providers intervene proactively. This trend is particularly impactful in chronic disease management such as diabetes and asthma, where continuous optimization of therapy enhances patient outcomes while reducing hospitalization costs. Pharmaceutical companies are increasingly partnering with digital health firms to develop smart therapeutics, combining connected devices with data-driven platforms, creating a seamless patient-provider feedback loop.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • Novo Nordisk A/S
  • Phillips Medisize
  • Medtronic Plc.
  • Adherium Limited
  • Tandem Diabetes Care, Inc.
  • Biocorp Life Sciences Pvt. Ltd
  • Resmed Corp
  • Ypsomed AG
  • AptarGroup, Inc

Report Scope:

In this report, the Global Connected Drug Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Connected Drug Delivery Devices Market, By Product Type:

  • Standalone Components & Software
  • Integrated Devices

Connected Drug Delivery Devices Market, By Route of Administration:

  • Parenteral
  • Inhalational

Connected Drug Delivery Devices Market, By Application:

  • Asthma
  • COPD
  • Diabetes Management
  • Others

Connected Drug Delivery Devices Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Connected Drug Delivery Devices Market.

Available Customizations:

Global Connected Drug Delivery Devices market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Connected Drug Delivery Devices Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Standalone Components & Software, Integrated Devices)
    • 5.2.2. By Route of Administration (Parenteral, Inhalational)
    • 5.2.3. By Application (Asthma, COPD, Diabetes Management, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Connected Drug Delivery Devices Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Connected Drug Delivery Devices Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Connected Drug Delivery Devices Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Connected Drug Delivery Devices Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Application

7. Europe Connected Drug Delivery Devices Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Connected Drug Delivery Devices Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Application
    • 7.3.2. United Kingdom Connected Drug Delivery Devices Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Application
    • 7.3.3. Italy Connected Drug Delivery Devices Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Application
    • 7.3.4. France Connected Drug Delivery Devices Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Connected Drug Delivery Devices Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Application

8. Asia-Pacific Connected Drug Delivery Devices Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Connected Drug Delivery Devices Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Application
    • 8.3.2. India Connected Drug Delivery Devices Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Application
    • 8.3.3. Japan Connected Drug Delivery Devices Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Connected Drug Delivery Devices Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Connected Drug Delivery Devices Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Application

9. South America Connected Drug Delivery Devices Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Connected Drug Delivery Devices Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Application
    • 9.3.2. Argentina Connected Drug Delivery Devices Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Application
    • 9.3.3. Colombia Connected Drug Delivery Devices Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Application

10. Middle East and Africa Connected Drug Delivery Devices Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Connected Drug Delivery Devices Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Application
    • 10.3.2. Saudi Arabia Connected Drug Delivery Devices Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Application
    • 10.3.3. UAE Connected Drug Delivery Devices Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Connected Drug Delivery Devices Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Teva Pharmaceutical Industries Ltd.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Novo Nordisk A/S
  • 14.3. Phillips Medisize
  • 14.4. Medtronic Plc.
  • 14.5. Adherium Limited
  • 14.6. Tandem Diabetes Care, Inc.
  • 14.7. Biocorp Life Sciences Pvt. Ltd
  • 14.8. Resmed Corp
  • 14.9. Ypsomed AG
  • 14.10.AptarGroup, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer